CORRECTING and REPLACING ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
Please replace the release dated April 26, 2024 with the following corrected version due to multiple revisions.
The updated release reads:
RENAGADE THERAPEUTICS CONTINUES COMMITMENT TO GANNA BIO AND GLYCAN BIOLOGY
GanNA founders include Carolyn Bertozzi, Ph.D., Richard D. Cummings, Ph.D., Ryan A. Flynn, M.D., Ph.D., and Namita Bisaria, Ph.D., M.B.A.
Additional investment strengthens ReNAgade’s delivery platform with unique conjugation platform based on novel glycobiology
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to unlock the potential of glycobiology through support for ongoing research at GanNA Bio, and an integration of the key founders of GanNA Bio into the ReNAgade ecosystem.
GanNA Bio was formed in 2021 and invested in by ReNAgade to harness novel glycobiology to enable extra-hepatic RNA delivery based on pioneering research licensed from Stanford University, Boston Children’s Hospital, and Beth Israel Deaconess Medical Center, which was developed in the labs of Carolyn Bertozzi, Ph.D., winner of the 2022 Nobel Prize in Chemistry and Professor of Chemistry in the Stanford School of Humanities and Sciences; Ryan A. Flynn, M.D., Ph.D., Assistant Professor at Boston Children’s Hospital; and Richard D. Cummings, Ph.D., S. Daniel Abraham Professor of Surgery at Beth Israel Deaconess Medical Center, and led by Namita Bisaria, Ph.D., M.B.A., a serial entrepreneur in the RNA therapeutics field. Its platform, based on new advances in glycobiology and synthesis, uses cell-specific glycans to develop next-generation conjugates and to unlock the delivery of short and long stranded RNA medicines.
“ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” GanNA founders Bertozzi and Cummings will now serve as advisors to ReNAgade.
“The progress in glycoRNA science from our seminal publication in the journal Cell is moving fast, and integration with ReNAgade’s pipeline will strengthen our position to develop a broad portfolio of cell specific delivery systems, leveraging the latest developments in glycobiology in order to expand the array of addressable diseases of RNA medicines,” said Ryan Flynn.
Dr. Bertozzi added, “The combination of GanNA’s innovative glycobiology-based targeting strategy with ReNAgade’s experience in the development of RNA medicines will be a powerful combination for the benefit of patients.” Dr. Cummings noted that “Glycobiology-based RNA medicines represent a new frontier, and it is rewarding to see the possibilities of ReNAgade developing these for clinical use.”
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and its leadership, visit www.renagadetx.com
About GanNA Bio
GanNA was created by Drs. Flynn and Bisaria, and invested by ReNAgade in 2021 following a sponsored research agreement in the lab of Dr. Flynn. The mission is to explore the potential of novel glycobiology therapies following the pioneering work at Stanford University by Drs. Flynn and Bertozzi on glycoRNA. The GanNA Bio Scientific Advisory Board included Drs. Bertozzi, Cummings, Flynn, and ReNAgade CSO, Pete Smith.
University Conflict of Interest Disclosure
Drs. Bertozzi, Cummings and Flynn consult for ReNAgade Therapeutics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240426251202/en/
Contact information
Investor Relations Contact:
Emily Brabbit, Argot Partners
(212) 600-1902
renagade@argotpartners.com
Media Relations Contact:
Sarah Sutton, Argot Partners
(212) 600-1902
renagade@argotpartners.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Featured in Discovery Channel Documentary Spotlighting Vietnam’s Tech Revolution16.9.2024 13:16:00 CEST | Press release
“Silicon Delta - The Story of Vietnam’s Tech Revolution,” the latest documentary on Vietnam and its leading tech corporation, FPT, has premiered on Discovery Channel and is available in 10 languages, including English, Japanese, German, Chinese, Korean, and so on. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240915240896/en/ (Graphic: Business Wire) The half-hour documentary traces Vietnam’s emergence to become Southeast Asia's fastest-growing digital economy. It offers a chronological view of Vietnam's evolution, current achievements, and positive future outlook, with the potential to become a global workforce powerhouse. Homegrown, FPT is listed among Asia’s Top 50 IT Services Companies, and the company’s journey into the global arena to a multibillion-dollar corporation today mirrors Vietnam's technological and socioeconomic developments. The documentary showcases FPT’s international expansion from its early days to est
Intelsat Unveils Terminal Strategy to Power Multi-Orbit Satellite Services16.9.2024 13:00:00 CEST | Press release
Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks and leading provider of in-flight connectivity (IFC), will be the first operator in the world to offer multi-orbit solutions for all relevant business units by the first half of 2025 thanks to a new satellite terminal strategy that will deliver advanced capabilities and improved economics. “Intelsat is making strategic bets on new technologies, including new investments in innovative terminal providers,” said Intelsat CEO David Wajsgras. “More and more customers will come to count on the broad reliability profile of multi-orbit solutions, and it is key to our future success. No single-orbit solution can match what Intelsat can offer when it comes to performance, resiliency and commercial flexibility.” Intelsat has an unmatched network of geostationary satellites as well as partnerships with low Earth orbit providers. With the launch of a new robust terminal strategy, Intelsat is now able to d
WETEX 2024 Showcases Dubai’s Flexible and Competitive Business Environment for Establishing New Corporate Headquarters16.9.2024 12:35:00 CEST | Press release
Amid the increasing inquiries from global companies and organisations about establishing headquarters and branches in the UAE and Dubai, the 26th Water, Energy, Technology, and Environment Exhibition (WETEX) will feature a series of workshops and panel discussions that will focus on the facilitations and incentives Dubai offers to companies looking to establish new headquarters or branches in the Emirate. The workshops will highlight Dubai's flexible regulatory and legislative frameworks, diverse investment options across various sectors, attractive opportunities and promising business prospects, robust digital infrastructure, safety and security, as well as other factors that enhance investor and business confidence, positioning Dubai as a global investment hub and a preferred destination for investors and entrepreneurs worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240916681538/en/ HE Saeed Mohammed Al Tayer, MD
Netradyne Technology Partners with Roos Fleetservice to Enhance Fleet and Driver Safety in Europe16.9.2024 10:00:00 CEST | Press release
Netradyne, a global provider of artificial intelligence (AI) technology solutions for fleet and driver safety, today announced a strategic partnership with Roos Fleetservice GmbH, a leading provider of fleet management in Germany, to bring Netradyne’s flagship product, Driver•i, to Roos Fleetservice’s European clients. The collaboration marks a substantial advancement in road safety and fleet management in the EU region and a significant milestone in Netradyne’s ongoing expansion across the European Union (EU), bringing its cutting-edge safety technology to a broader range of fleet organisations. Netradyne already runs commercial operations across the U.S., Germany, the U.K., India, Australia, New Zealand and Canada, with several hundred thousand installations across fleets of all sizes. Driver•i leverages AI, ML and Edge Computing to analyse 100% of driving time and set new vehicle safety standards. To date, Driver•i has processed over 15 billion miles of driving data, making the AI p
The Estée Lauder Companies Inc. Recommends Stockholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation And Do Not Tender Shares16.9.2024 09:45:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) (the “Company”) today announced that it has received notice that TRC Capital Investment Corporation (“TRC”) commenced an unsolicited “mini-tender” offer to purchase up to 1,500,000 shares of the Company’s Class A common stock, which represents approximately 0.64% of the outstanding Class A common stock, at a price of $83.65 per share in cash. The Company does not endorse TRC’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares because TRC’s offer is at a price below the current market price for Class A common stock and is subject to numerous conditions. The Company is in no way associated with TRC, its mini-tender offer, or the mini-tender offer documents. Mini-tender offers seek to acquire less than 5% of a company’s shares outstanding. Consequently, they can avoid many of the disclosure and procedural requirements of U.S. Securities and Exchange Commission (“SEC”) rules intended for the protection of st
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom